TARS1 (Threonyl-tRNA Synthetase 1) is a human gene encoding threonyl-tRNA synthetase (ThrRS), an essential aminoacyl-tRNA synthetase that catalyzes the attachment of threonine to its cognate tRNA. This enzyme is critical for protein synthesis during translation. Beyond its canonical role in translation, threonyl-tRNA synthetase has been discovered to have diverse extra-translational functions including regulation of angiogenesis, cell migration, immune responses, and neuronal development. This page covers the gene's molecular function, disease associations, expression patterns, and emerging research on its role in neurodegeneration.
| Gene Symbol | TARS1 |
|---|---|
| Full Name | Threonyl-tRNA Synthetase 1 |
| Chromosomal Location | 5p13.3 |
| NCBI Gene ID | [6897](https://www.ncbi.nlm.nih.gov/gene/6897) |
| OMIM | [187960](https://www.omim.org/entry/187960) |
| Ensembl ID | [ENSG00000139921](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000139921) |
| UniProt | [Q9P2D0](https://www.uniprot.org/uniprotkb/Q9P2D0/entry) |
| Protein Length | 724 amino acids |
| Protein Class | Aminoacyl-tRNA synthetase, class II |
| Associated Diseases | Charcot-Marie-Tooth disease, neurodevelopmental disorders, early-onset epileptic encephalopathy, hereditary spastic paraplegia |
TARS1 encodes threonyl-tRNA synthetase 1, a class II aminoacyl-tRNA synthetase that catalyzes the ATP-dependent attachment of threonine to tRNAThr. This reaction is essential for the fidelity and efficiency of protein synthesis. ThrRS is one of several aminoacyl-tRNA synthetases that have been shown to have "moonlighting" functions beyond translation, including regulation of transcription, RNA splicing, cell signaling, angiogenesis, and immune responses. In the nervous system, TARS1 is expressed in neurons and glial cells, and pathogenic variants cause peripheral neuropathies and neurodevelopmental disorders. The enzyme's role in neuronal survival and axonal maintenance makes it a subject of interest for understanding mechanisms of neurodegeneration.
Threonyl-tRNA synthetase (ThrRS) catalyzes the following two-step reaction:
The enzyme recognizes its tRNA through multiple identity elements, including the discriminator base A73, the anticodon nucleotides G34, U35, and U36, and base pairs in the acceptor stem. Human ThrRS contains N-terminal and C-terminal extensions that participate in dimerization and contribute to its regulatory functions.
Human ThrRS has a modular structure consisting of:
The enzyme forms homodimers, and dimerization is required for both catalytic activity and some extra-translational functions.
Beyond translation, threonyl-tRNA synthetase has several important non-canonical roles:
Angiogenesis regulation: ThrRS can be secreted and promotes endothelial cell migration and tube formation. The N-terminal fragment of ThrRS has been shown to have pro-angiogenic activity.
Immune modulation: Extracellular ThrRS can act as a cytokine-like molecule, stimulating immune cell migration and activation.
RNA splicing: In some organisms, ThrRS participates in RNA splicing, though this function appears to be less prominent in humans.
Translational control: ThrRS can be phosphorylated and translocate to the nucleus, where it may influence gene expression.
TARS1 mutations have been identified as causative for Charcot-Marie-Tooth disease (CMT), the most common inherited peripheral neuropathy. CMT caused by TARS1 variants is typically classified as CMT type 2 (axonal CMT) or intermediate CMT. The disease manifests as:
The pathogenic mechanisms involve impaired aminoacylation activity leading to defects in neuronal protein synthesis, particularly in long axons that require local translation for maintenance.
Biallelic TARS1 mutations cause a syndrome characterized by:
These phenotypes suggest that TARS1 is essential for normal brain development, possibly through its role in neuronal protein synthesis or through extra-translational functions in signaling pathways important for neurogenesis.
De novo missense mutations in TARS1 have been reported in individuals with early-onset epileptic encephalopathy, including Ohtahara syndrome and West syndrome. The seizures in these cases are often refractory to treatment and associated with severe developmental impairment.
Specific TARS1 variants cause pure hereditary spastic paraplegia (HSP), characterized by progressive lower limb spasticity and weakness due to degeneration of corticospinal tract neurons. This suggests that TARS1 function is particularly important for upper motor neuron survival.
Threonyl-tRNA synthetase is ubiquitously expressed, reflecting its essential role in protein synthesis. In the nervous system:
TARS1 expression is upregulated during brain development and remains high in adult brain, particularly in the cortex, hippocampus, and cerebellum.
While TARS1 is not classically considered a neurodegeneration gene, several lines of evidence suggest it may contribute to neurodegenerative processes:
Neurons have particularly high requirements for protein synthesis due to their elongated axons and complex dendritic arbors. Local translation in axons is essential for synaptic plasticity, axonal maintenance, and response to injury. TARS1 mutations may impair this process, leading to axonal degeneration.
Some TARS1 variants affect mitochondrial function, possibly through impaired mitochondrial tRNA charging or disruption of the interactions between cytosolic and mitochondrial translation systems. Mitochondrial dysfunction is a common theme in many neurodegenerative diseases.
Although direct evidence linking TARS1 to Alzheimer's disease or Parkinson's disease is limited, the broader class of aminoacyl-tRNA synthetases has been implicated in neurodegeneration:
TARS1 interacts with several proteins relevant to neuronal function:
| Interaction Partner | Function |
|---|---|
| EEF1A1 | Translation elongation factor |
| tRNAThr | Substrate for aminoacylation |
| Importin | Nuclear import |
| VEGF | Pro-angiogenic signaling |
| Ribosomal proteins | Translation machinery |
Key publications on TARS1 and threonyl-tRNA synthetase:
ThrRS structure and mechanism: The catalytic mechanism and structure of human ThrRS have been elucidated through X-ray crystallography and cryo-EM studies, revealing the basis for amino acid specificity and the editing function.
Disease-causing mutations: Next-generation sequencing studies have identified multiple pathogenic TARS1 variants in families with CMT and neurodevelopmental disorders, with functional studies demonstrating reduced aminoacylation activity.
Extra-translational functions: Studies have characterized the pro-angiogenic and immunomodulatory functions of ThrRS, revealing its role as a secreted signaling molecule.
Therapeutic approaches: No specific treatments for TARS1-associated disorders exist, but approaches under investigation include:
Mouse models with Tars1 knockout are embryonic lethal, demonstrating the essential nature of this gene. Heterozygous knockout mice show subtle deficits in neural development. Zebrafish models have been used to study TARS1 function in neuronal development and have revealed defects in axon guidance in TARS1 morphants.
TARS1 can be included in panels for hereditary neuropathy and neurodevelopmental disorders. Whole exome sequencing has identified TARS1 as a causative gene in some cases of apparently sporadic CMT and early-onset encephalopathy.
Currently, treatment is supportive and includes:
The identification of TARS1 as a disease gene has implications for genetic counseling, as many pathogenic variants are inherited in an autosomal recessive pattern.